GlassScriptPhysician profile
Holly Rodell
NPI 1700454667
$2,775.21
in general payments reported to CMS, 2019-2025
12 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $549 · 2023: $939 · 2024: $826 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $776.55 | 2021-2025 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $589.59 | 2021-2024 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $370.57 | 2022-2025 | Infuse, Vyzulta |
| Sun Pharmaceutical Industries INC. | $246.81 | 2022-2024 | |
| Abbvie INC. | $213.80 | 2022-2023 | Vuity |
| Oyster Point Pharma, INC. | $138.24 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $121.82 | 2024 | Xdemvy |
| Dompe US, INC. | $117.36 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $111.89 | 2021 | |
| Astellas Pharma US INC | $48.70 | 2024 | Izervay |
| Johnson & Johnson Vision Care, INC. | $22.28 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Rodell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.